ASCO 2022 | Landscape of targeted therapies in lung cancer

Targeted therapy has been revolutionary for the treatment of lung cancer leading to a reduction in mortality. In this interview, Bob T. Li, MD, MPH, Memorial Sloan Kettering Cancer Center, New York, NY, reflects on novel therapeutic targets such as KRAS, a previously “undruggable” target that is now targetable with therapies such as sotorasib and adagrasib. In addition, Dr Li explores other targeted therapies under investigation, including agents targeting EGFR, ALK, ROS, BRAF, RET, and HER2. Dr Li highlights the use of circulating tumor DNA (ctDNA) to elucidate mechanisms of drug resistance. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.